Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity:: demonstrable differences in vitro and clinically

被引:124
作者
Noor, Mustafa A.
Flint, Oliver P.
Maa, Jen-Fue
Parker, Rex A.
机构
[1] Bristol Myers Squibb Co, Pharmaceut Res Inst, Dept Discovery & Exploratory Clin Res, Princeton, NJ 08543 USA
[2] Bristol Myers Squibb Co, Pharmaceut Res Inst, Dept Discovery Toxicol, Princeton, NJ 08543 USA
[3] Bristol Myers Squibb Co, Pharmaceut Res Inst, Dept Virol Med Affairs, Princeton, NJ 08543 USA
关键词
D O I
10.1097/01.aids.0000244200.11006.55
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: The HIV protease inhibitor (PI)atazanavir does not impair insulin sensitivity acutely but ritonavir and lopinavir induce insulin resistance at therapeutic concentrations. Objective: To test the hypothesis that atazanavir combined with a lower dose of ritonavir would have significantly less effect on glucose metabolism than lopinavir/ritonavir in vitro and clinically. Methods: Glucose uptake was measured following insulin stimulation in differentiated human adipocytes in the presence of ritonavir (2 mu mol/l) combined with either atazanavir or lopinavir (3-30 mu mol/l). These data were examined clinically using the hyperinsulinemic euglycemic clamp and oral glucose tolerance testing (OGTT) in 26 healthy HIV-negative men treated with atazanavir/ritonavir (300/100 mg once daily) and lopinavir/ritonavir (400/100 mg twice daily) for 10 days in a randomized cross-over study. Results: Atazanavir inhibited glucose uptake in vitro significantly less than lopinavir and ritonavir at all concentrations. Ritonavir (2 p,mu mol/l) combined with either atazanavir or lopinavir (3-30 mu mol/l) did not further inhibit glucose uptake. During euglycemic clamp, there was no significant change from baseline insulin sensitivity with atazanavir/ritonavir (P=0.132), while insulin sensitivity significantly decreased with lopinavir/ritonavir from the baseline (-25%; P < 0.001) and from that seen with atazanavir/ritonavir (-18%; P=0.023). During OGTT, the HOMA insulin resistance index significantly increased from baseline at 120 min with atazanavir/ritonavir and at 150 min with lopinavir/ritonavir. The area under the curve of glucose increased significantly with lopinavir/ritonavir but not with atazanavir/ritonavir. Conclusions: Both glucose uptake in vitro and clinical insulin sensitivity in healthy volunteers demonstrate differential effects on glucose metabolism by the combination PI atazanavir/ritonavir and lopinavir/ritonavir. (c) 2006 Lippincott Williams & Wilkins.
引用
收藏
页码:1813 / 1821
页数:9
相关论文
共 33 条
[1]  
BAHADOR G, 2003, 43 ANN INT C ANT AG
[2]   Insulin sensitivity indices calculated from basal and OGTT-induced insulin, glucose, and FFA levels [J].
Belfiore, F ;
Iannello, S ;
Volpicelli, G .
MOLECULAR GENETICS AND METABOLISM, 1998, 63 (02) :134-141
[3]   Protein binding in antiretroviral therapies [J].
Boffito, M ;
Back, DJ ;
Blaschke, TF ;
Rowland, M ;
Bertz, RJ ;
Gerber, JG ;
Miller, V .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2003, 19 (09) :825-835
[4]   Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the Multicenter AIDS Cohort Study [J].
Brown, TT ;
Cole, SR ;
Li, XH ;
Kingsley, LA ;
Palella, FJ ;
Riddler, SA ;
Visscher, BR ;
Margolick, JB ;
Dobs, AS .
ARCHIVES OF INTERNAL MEDICINE, 2005, 165 (10) :1179-1184
[5]   The direct and indirect effects of insulin on hepatic glucose production in vivo [J].
Cherrington, AD ;
Edgerton, D ;
Sindelar, DK .
DIABETOLOGIA, 1998, 41 (09) :987-996
[6]  
DEFRONZO R A, 1987, Diabetes Metabolism Reviews, V3, P415
[7]  
DEFRONZO RA, 1979, AM J PHYSIOL, V237, pE214
[8]  
Doran DA, 2004, ANTIVIR THER, V9, pL6
[9]   Cardiovascular disease risk factors in HIV patients -: association with antiretroviral therapy.: Results from the DAD study [J].
Friis-Moller, N ;
Weber, R ;
Reiss, P ;
Thiébaut, R ;
Kirk, O ;
Monforte, AD ;
Pradier, C ;
Morfeldt, L ;
Mateu, S ;
Law, M ;
El-Sadr, W ;
De Wit, S ;
Sabin, CA ;
Phillips, AN ;
Lundgren, JD .
AIDS, 2003, 17 (08) :1179-1193
[10]   Mechanisms and strategies for insulin resistance in acquired immune deficiency syndrome [J].
Grinspoon, S .
CLINICAL INFECTIOUS DISEASES, 2003, 37 :S85-S90